Organigram Global Inc. is introducing 10 product SKUs in the Australian medical market across its Edison and BOXHOT brands.
The move marks the first time the company’s branded products will reach one of the world’s largest medical markets, although the Canadian cannabis company already supplies cannabis flower to the Australian market through existing B2B supply relationships.
Organigram says these formats reflect a belief that future global growth in medical cannabis will be driven by ready-to-consume products and anchored in science and standards.
The company’s Edison vapes will feature single-strain live terpenes extracted from Canada’s top-selling cultivars, with the terpenes shipped to Australia. Organigram will also offer edible pastilles with an array of established formulations developed with specific patient experiences in mind. The BOXHOT SKUs will feature three of the company’s top-selling botanical blends in Canada in its proprietary, wide-bodied 1.2g cartridges.
While flower remains a core category in the Australian medical cannabis market, products like cannabis vapes and pastilles (gummy-like candies) are gaining traction, driven by demand for consistent dosing, ease of administration, and discreet, ready-to-use formats. Megan McCrae, Senior Vice President, Corporate Strategy & International Growth at Organigram, says the company believes these trends bode well for the company, given its experience with these kinds of products, which she says aligns with Organigram’s recently announced strategic transaction agreement with Germany’s Sanity Group.
“Australia represents an exciting international opportunity in medical cannabis, and we are entering the market at a pivotal moment with an informed strategy. The launch of Organigram brands in Australia coincides with our proposed acquisition of Sanity Group, one of Germany’s leading cannabis companies, marking a significant step in our international expansion.
“Together, these strategic moves underscore Organigram’s commitment to broadening its global reach and reinforcing our reputation as a trusted supplier of medical cannabis,” McCrae continued. “By integrating established brands from the Canadian market, with a diverse range of science-led innovative product formats, we are positioning Organigram to serve leading regulated medical cannabis markets globally, delivering consistent quality and reliability to patients across Australia and beyond.”
Organigram’s products will be available through its distribution partnership with Leafio, the wholesale distribution arm of Montu Australia, one of Australia’s medical cannabis distributors. Through the agreement, Organigram’s medical cannabis products are expected to be available to more than 4,000 pharmacies via Leafio’s nationwide supply chain.
“Australia is a rapidly evolving medical market where we see momentum in ready-to-consume formats beyond traditional flower,” said Borna Zlamalik, Senior Vice President, Innovation and International R&D. “As patient and clinician preferences continue to move toward reliable, convenient, non-flower options that are grounded in science, data, and rigorous quality standards, Organigram is well-positioned to participate in this next phase of growth. Our industry-leading focus on science and clinical validation—combined with our experience developing high-quality, non-flower products in Canada—gives us a unique advantage as we introduce our established Canadian brands and product offerings to the Australian market.”
Organigram will debut its new product lineup as a sponsor at the United in Compassion (UIC) Medicinal Cannabis Symposium, taking place February 26–28 in Brisbane, where Zlamalik will be a featured speaker at the event’s Scientific Program, delivering an address titled “From Potency to Predictability: Engineering Confidence in Medical Cannabis.” The conference provides a platform to introduce Organigram’s medical cannabis product portfolio to clinicians, researchers, and industry participants across Australia.
Organigram Global is a silver sponsor of the Symposium, along with Australian medical cannabis company Cannatrek and US-based Curaleaf International at a rate of A$20,000. US-based Tilray Medical, which also operates in Canada, is a Drinks Sponsor for the event. Canada’s Canopy Growth is among those exhibiting at the event, as well. The four-day event includes presentations from medical cannabis experts from around the world.
Canada is the largest exporter of cannabis into the Australian medical market.
The total quantity of cannabis imported into Australia under the country’s cannabis for medical purposes regulations increased from almost 45 thousand kilograms in 2023 to more than 77 thousand in 2024, according to the most recent figures from Australia’s Office of Drug Control (ODC).
Cannabis from Canada continues to account for the bulk of these imports. In 2023, Australia imported 35,941 kg of cannabis from Canada. In 2024, that figure jumped to 62,111 kg, a 73% increase, with 80% of the country’s total cannabis imports coming from Canada. Australia produced another 42,400 kg of cannabis domestically in 2024 (the most recent figures), with 21,900 kg of this held in stock at the end of the year, along with 18,101 kg of imported cannabis also held in stock.
Increased international presence
Organigram Global Inc. reported gross revenue of $97.3 million for the three months ended December 31, 2025 (Q1 FY2026), net revenue of $63.5 million, and net income of $20 million.
International wholesale sales were $5 million, up from $3.3 million in the three months ended December 31, 2024. During the three months ended December 31, 2025, Organigram had four customers that, individually, accounted for more than 10% of the company’s net revenue. The company’s employee headcount in Q1 2026 was 1,137.
Despite these gains, during the company’s earnings call for the most recently reported quarter, Organigram’s CEO James Yamanaka noted an unexpected decline in international volumes due to “a higher-than-expected proportion of flower that did not meet international specifications.”
“…the first thing to note is that the requirements on international flower and the process that you can take in terms of processing the product are far more stringent in a lot of the international markets, and particularly in Germany, which is the fastest growing and largest of the international markets at the moment,” added Yamanaka, formerly Global Head of Strategy for British American Tobacco. “What has happened is, as we mentioned, we had a fantastic increase in yields over the past year, which has meant we’ve had a lot more flower on hand, which has caused some issues in microbiome growth. We have identified what we believe are the core drivers. We’re working on it to fix it. I do believe it’s a temporary issue, and we should get back to supplying the market in the future.”
Greg Guyatt, CFO for Organigram Global, said this was worth about C$3.5 million in revenue.
“We have taken that flower and repurposed it towards the Canadian market,” said Guyatt during the earnings call. “There are no issues with it. It just didn’t meet the needs for our international customer. We’re not expecting any inventory write-offs as a result of that.”
The partnership between British American Tobacco and Organigram was announced in late 2023, with an investment of nearly $125 million from the British multinational.
In 2023, Organigram said most of a $124.6 million investment from British American Tobacco (BAT) would be used to create a strategic investment pool named Jupiter, focused on emerging cannabis opportunities, including geographic expansion.
Organigram acquired the BOXHOT brand in its 2024 acquisition of Motif Cannabis.
